- Amgen Inc's AMGN Q3 revenues increased 4% to $6.71 billion, slightly beating the consensus of $6.68 billion.
- The increase is driven by higher unit demand, partially offset by lower net selling prices.
- Adjusted EPS increased 11% to $4.67, ahead of the consensus estimate of $4.27.
- Net earnings fell 3% to $3.31 per share with a $400 million licensing-related expense from collaborating with Japan's Kyowa Kirin Co Ltd.
- Amgen said sales volume for Q3 rose 8%, but net selling prices fell 7% as competition, including from cheaper generics & biosimilars, pushed down prices for its arthritis, migraine, and infection-fighting drugs.
- Sales of arthritis drug Enbrel fell 3% from a year earlier to $1.29 billion. Sales of newer cancer drug Lumakras totaled $36 million for Q3.
- Cholesterol treatment Repatha saw sales jump of 33% Y/Y despite a lower net selling price, as volume growth surged, including a 64% jump in the U.S.
- Sales of psoriasis drug Otezla increased 13% despite lower prices as well. Amgen is preparing for the anticipated U.S. approval of the mild-to-moderate psoriasis indication.
- Guidance: Amgen slightly raised its FY21 adjusted EPS to $16.50 - $17.10 (consensus of $16.43) from a previous $16.00 to $17.00.
- The Company lowered the top end of its revenue forecast to $26.2 billion from a previous $26.6 billion.
- Price Action: AMGN shares are trading lower by 1.06% at $211.99 premarket on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in